When was LPOXY Therapeutics founded?

LPOXY Therapeutics was founded in 2020 and raised its 1st funding round 5 years after it was founded.

Where is LPOXY Therapeutics located?

LPOXY Therapeutics is headquartered in Platte City, United States.

How many employees does LPOXY Therapeutics have?

As of Jun 30, 2026, the latest employee count at LPOXY Therapeutics is 1.

Is LPOXY Therapeutics a funded company?

LPOXY Therapeutics is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Sep 03, 2025.

When was the latest funding round of LPOXY Therapeutics?

LPOXY Therapeutics' latest funding was a $***** Series A round on Sep 03, 2025, with participation from 1 investor. Its primary sector is Infectious Diseases. In United States, the Infectious Diseases sector has seen $759M in funding in 2026 to date.

Where does LPOXY Therapeutics rank among its competitors?

LPOXY Therapeutics ranks 53rd amongst 172 active competitors, of which 55 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Basilea, which secured $13.3M in May, 2026.

Who are the top competitors of LPOXY Therapeutics?

LPOXY Therapeutics' top competitors include Insmed, Evofem and Quell. Among them, Basilea secured the most recent funding round in May, 2026.

LPOXY Therapeutics - 2026 Company Profile, Funding & Competitors

Company Details

Developer of therapies for infectious disease prevention. It offers an oral therapeutic, Sidiprev, which aims to prevent Clostridioides difficile infection by delivering oxygen directly to the bowel.

Website: www.lpoxy.com/
Phone Number: +1 **********

Key Metrics

Founded Year

2020

Location

Platte City, United States

Stage

Series A

Total Funding

$28M in 1 round

Latest Funding Round

Series A, Sep 03, 2025, $*****

Investors

5 Horizons Capital

Ranked

53^rd among 172 active competitors

Employee Count

1 as on Jun 30, 2026

Similar Companies

Insmed & 201 more

View LPOXY Therapeutics' full profile

LPOXY Therapeutics has raised a total funding of $28M over 1 round. Its latest funding round was a Series A round on Sep 03, 2025 for $*****. 1 investor participated in its latest round. LPOXY Therapeutics has 1 institutional investor.

Here is the list of recent funding rounds of LPOXY Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 03, 2025	8509758	Series A	4371179	6539505	1536743	1934389

Access funding benchmarks and valuations. Sign up today!

View details of LPOXY Therapeutics's funding rounds and investors

LPOXY Therapeutics' employee count trend

LPOXY Therapeutics has 1 employees as of Jun 26. Here is LPOXY Therapeutics's employee count trend over the years:

Employee count trend for LPOXY Therapeutics

Uncover LPOXY Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of LPOXY Therapeutics include Insmed, Evofem and Quell. Here is the list of Top 10 competitors of LPOXY Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Insmed 1999, Bridgewater (United States), Public	Developer of small molecule inhibitors for rare lung diseases	-	Foresite Capital, Quaker Partners Management ... & 13 others	66/100
2nd	Evofem 2009, San Diego (United States), Public	Developer of sexual and reproductive health therapeutics	$100M	mercerstcap.com, Aditx Therapeutics & 10 others	65/100
3rd	Quell 2019, London (United Kingdom), Series B	Developer of engineered regulatory T cell therapies for immune diseases	$344M	Syncona, Fidelity Investments & 17 others	64/100
4th	Enveda 2019, Boulder (United States), Series D	AI-based platform to decipher the chemistry of nature and develop new medicines	$517M	Premji Invest, Kinnevik & 30 others	63/100
5th	Kanvas Biosciences 2021, Ithaca (United States), Series A	Provider of imaging solutions for microbial research and infectious diseases	$77.5M	DCVC, Uncommon Denominator & 11 others	63/100
6th	Samsung Bioepis 2012, Incheon (South Korea), Acquired	Developer of biosimilar drugs for the treatment of multiple diseases	-	Biogen, Samsung BioLogics	62/100
7th	Basilea 1999, Basel (Switzerland), Public	Developer of antibiotics, antifungals, and oncology drugs for treating multiple diseases	-	Athyrium Capital Management, Medical Countermeasures ... & 2 others	59/100
8th	SpyBiotech 2017, Oxford (United Kingdom), Series A	Developer of vaccines for bacterial infections and cancer by using proprietary protein superglue technology	$39M	Braavos, Oxford Science Enterprises & 6 others	59/100
9th	Accropeutics 2017, Suzhou (China), Series C	Developer of drugs for inflammation, autoimmune diseases, and cancer	$62M	Orbimed, Shenzhen Capital Group & 7 others	58/100
10th	MRM Health 2020, Ghent (Belgium), Series B	Developer of optimized consortia therapeutics targeting inflammatory, CNS, and metabolic diseases	$79.2M	DuPont, Ackermans & van Haaren & 11 others	58/100
53rd	LPOXY Therapeutics 2020, Platte City (United States), Series A	Developer of therapies for infectious disease prevention	$28M	5 Horizons Capital	41/100